Skip to main content

Table 1 Baseline characteristics of patients

From: Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

 

Immune checkpoint inhibitor group

(n = 129)

Irinotecan-based chemotherapy group

(n = 234)

P-value

No. (%)

No. (%)

Age, years

  

0.099

  Mean ± SD

59 ± 11.04

57 ± 11.45

 

  Range

22–88

26–83

 

Sex

  

0.682

  Male

76 (58.9)

143 (61.1)

 

  Female

53 (41.1)

91 (38.9)

 

aECOG performance status

  

0.469

  0/1

31 (24.2)/ 68 (53.1)

40 (17.2)/ 166 (71.6)

 

  2/3

28 (21.9)/ 1 (0.8)

25 (10.8)/ 1 (0.4)

 

bSite of primary tumor

  

0.234

  Gastric

119 (97.5)

202 (94.8)

 

  Gastroesophageal junction

3 (2.5)

11 (5.2)

 

cWHO histology

  

0.881

 Tubular adenocarcinoma

   

  Well differentiated

3 (2.3)

7 (3.0)

 

  Moderately differentiated

35 (27.1)

61 (26.1)

 

  Poorly differentiated

33 (25.6)

63 (26.9)

 

 Poorly cohesive carcinoma/Signet-ring cell carcinoma

50 (38.8)

88 (37.6)

 

 Mixed adenocarcinoma

6 (4.7)

7 (3.0)

 

dLauren Classification

  

0.320

  Intestinal

28 (32.2)

35 (28.7)

 

  Diffuse

52 (59.8)

71 (58.2)

 

  Mixed

7 (8.0)

16 (13.1)

 

Measurable lesion

  

0.581

  Yes

75 (58.1)

128 (54.7)

 

  No

54 (41.9)

106 (45.3)

 

eHER2 status

  

0.446

  Positive

18 (14.1)

26 (11.3)

 

  Negative

110 (85.9)

204 (88.7)

 

fEBV in situ hybridization

  

0.129

  Positive

2 (2.0)

11 (6.0)

 

  Negative

96 (98.0)

171 (94.0)

 

gMSI/MMR status

  

0.024

  MSI-H and/or dMMR

9 (9.1)

5 (2.7)

 

  Others

90 (90.9)

177 (97.3)

 

hPD-L1 status

  

0.001

  Positive

54 (62.1)

60 (39.4)

 

  Negative

33 (37.9)

92 (60.5)

 

iPrior gastrectomy

  

0.303

  Yes

74 (57.4)

120 (51.7)

 

  No

55 (42.6)

112 (48.3)

 

Peritoneal metastasis

  

0.262

  Yes

90 (69.8)

176 (75.2)

 

  No

39 (30.2)

58 (24.8)

 

Liver metastasis

  

0.089

  Yes

35 (27.1)

84 (35.9)

 

  No

94 (72.9)

150 (64.1)

 

Duration of 2nd line treatment

  

0.841

  Median (range), months

4.1 (0.6–23.0)

3.5 (0.3–25.4)

 

Prior first-line treatment

  

0.305

  Trastuzumab plus FP (or XP)

16 (12.4)

21 (9.0)

 

  XELOX or FOLFOX

96 (74.4)

167 (71.4)

 

  XP or SP

12 (9.3)

24 (10.3)

 

  Others*

5 (3.8)

22 (9.4)

 

jSerum sodium, mEq/L

   

  Median (range)

138.0 (127.0-146.0)

138.4 (121.0-149.0)

 

  ≥135

89 (73.0)

172 (81.9)

0.071

  <135

33 (27.0)

38 (18.1)

 

kSerum albumin, g/dL

   

  Median (range)

3.3 (1.8–4.6)

3.4 (1.9–4.6)

 

  ≥3.5

50 (39.7)

104 (45.4)

0.315

  <3.5

76 (60.3)

125 (54.6)

 
  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; HER2, human epidermal growth factor receptor 2; EBV, Epstein-Barr virus; MSI/MMR, microsatellite instability/mismatch repair; FP, 5-fluorouracil and cisplatin; XP, capecitabine and cisplatin; XELOX, capecitabine and oxaliplatin; FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; SP, S-1 and cisplatin; SOX, S-1 and oxaliplatin; FEP, 5-fluorouracil, etoposide and cisplatin
  2. aMissing ECOG PS data for 3 patients; bMissing site of primary tumor for 7 in the ICI and 21 in the irinotecan-based chemotherapy grup; cMissing WHO histology for 2 in the ICI and 8 in the irinotecan-based chemotherapy group; dMissing Lauren classification for 42 in the ICI and 112 in the irinotecan-based chemotherapy group; eMissing HER2 status for 1 patient in the ICI and 4 patients in the irinotecan-based chemotherapy group; fMissing EBV status for 31 patients in the ICI and 52 patients in the irinotecan-based chemotherapy group; gMissing MSI/MMR status for 30 patients in the ICI and 52 patients in the irinotecan-based chemotherapy group; hMissing PD-L1 status for 42 patients in the ICI and 82 patients in the irinotecan-based chemotherapy group; iMissing prior gastrectomy for 2 in the irinotecan-based chemotherapy group; jMissing serum sodium for 7 patients in the ICI and 24 patients in the irinotecan-based chemotherapy group; kMissing serum albumin for 3 in the ICI and 5 in the irinotecan-based chemotherapy group
  3. *Others include SOX, FP, FEP, and clinical trials (FOLFOX+/-Zolbetuximab, FOLFOX+/-FPA144, XELOX+/-Nivolumab, XELOX+/-BGB-A317, FOLFOX+/-Varlitinib, SOX+/-Nivolumab)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us